Charts

MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. “The U.S. is an important region fo

Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, ...

– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed to Professor Colin Masters for evaluation in Alzheimer’s and related diseases – MELBOURNE, Australia AND SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying tre

MELBOURNE, Australia and SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. “We are pleased to announce that our f

MELBOURNE, Australia and SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Company has been granted authorization to conduct its Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA) by the Austrian Federal Office for Safety in Healthcare and the French National Agency for th

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2022 (Q2 FY23).

Alterity Therapeutics(NASDAQ: ATHE) announced that a study recently published in the ...

Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading higher by 5.67% to $4.12 Monday morning after the company announced ATH434 ...

Gainers G Medical Innovations (NASDAQ:GMVD) stock moved upwards by 98.7% to $5.96 during Monday's pre-market session. The market value ...

Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson’s diseaseMELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a study recently published in the journal Neurotherapeutics demonstrated that its

Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA)

Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.

Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office (USPTO). The patent was allowed following expedited review by the USPTO.

On Tuesday, 49 companies hit new 52-week lows. Key Facts About Today's 52-Week Lows: Tesla (NASDAQ:TSLA) is the ...

Gainers Lannett (NYSE:LCI) stock moved upwards by 14.5% to $0.71 during Friday's after-market session. The market value of their ...

Gainers Talkspace, Inc. (NASDAQ: TALK) shares rose 48.3% to $0.89 in pre-market trading. Talkspace recently named Jon Cohen as ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It's time to check out the biggest pre-market stock movers that traders will want to know about on Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th September 2022 (Q1 FY23).

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the 147th Annual Meeting of the American Neurological Association (ANA) on October 24, 2022. For over 140 years, the ANA has been the premier professional socie

Gainers Nuwellis (NASDAQ:NUWE) stock rose 13.9% to $0.28 during Thursday's after-market session. The company's market cap stands at ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the St. Vincent's Hospital Melbourne Human Research Ethics Committee (HREC) to conduct the Phase 2 clinical trial of ATH434 for the treatment of individuals with Multiple System Atrophy (MSA). Alterity has also opened enrolment at its first clinical

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was presented at the International Congress of Parkinson's Disease and Movement Disorders. The presentation correlates data from wearable sensors with clinical assessments of motor funct

Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading sharplylower by 14.29% to $0.48, reversing following earlier ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The approval of this IND authorizes Alterity to cond

Gainers BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) rose 58.2% to $8.70 in pre-market trading. BYND Cannasoft shares jumped ...

Pfizer (NYSE: PFE) announced positive top-line data from the Phase 3 clinical trialRENOIR investigating its bivalent RSV ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.

Upgrades Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the ...

During Thursday's trading, 50 companies set new 52-week lows. 52-Week Highlights: The largest company in terms of ...

Alterity Therapeutics (NASDAQ: ATHE) doses first subject in its Phase 2 clinical trial of lead candidate ATH434 in Multiple System ...

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The ...

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The ...

Gainers American Rebel Holdings, Inc.(NASDAQ: AREB) rose 142% to $5.35 in pre-market trading following uplisting ...

Alterity Therapeutics's(NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal ...

Gainers Hour Loop, Inc.(NASDAQ: HOUR) shares jumped 99.8% to $7.99after the company priced its IPO at $4 per ...

Gainers Absci (NASDAQ:ABSI) stock increased by 28.2% to $7.87 during Friday's regular session. As of 12:30 EST, ...

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's the final day of trading this week and we're starting it off with an overview of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Gainers Absci Corporation (NASDAQ: ABSI) rose 40.9% to $8.65 in pre-market trading after the company reported a research ...

Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of ...

Toward the end of trading Thursday, the Dow traded down 0.35% to 36,278.43 while the NASDAQ rose 0.22% to 15,133.94. The S&P ...

Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume ...

Midway through trading Thursday, the Dow traded down 0.34% to 36,284.59 while the NASDAQ rose 0.18% to 15,127.00. The S&P, however, ...

Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to ...

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 54.3% to $0.9490 in pre-market trading after declining more than ...

Gainers Sensus Healthcare (NASDAQ:SRTS) shares moved upwards by 18.6% to $8.1 during Wednesday's pre-market session. ...

Gainers OptiNose (NASDAQ:OPTN) shares moved upwards by 9.81% to $1.79 during Monday's after-market session. Trading volume for this ...

Upgrades For Investors Bancorp Inc (NASDAQ:ISBC), Stephens & Co. upgraded the previous rating of Equal-Weight to ...

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn ...

Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on ...

Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from ...

Gainers Alterity Therapeutics Limited (NASDAQ: ATHE) shares rose 34.8% to $1.84 in pre-market trading after gaining around 3% on ...

Gainers Second Sight Medical (NASDAQ:EYES) shares rose 19.44% to $5.16 during Wednesday's after-market session. This security traded ...